Sincalide ammonium

Research use only, not for human use.

Sincalide ammonium (Cholecystokinin octapeptide ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography.

Sincalide ammonium (Cholecystokinin octapeptide ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography.

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium), as a novel cardiovascular hormone, has a significant inhibitory effect on myocardial fibrosis in noninfarcted areas. Sincalide ammonium also plays a positive role in fighting inflammation, apoptosis and collagen deposition. CCK‐8 (ammonium) protects H9c2 cardiomyoblasts from Ang II‐induced apoptosis partly via activation of the CCK1 receptor and the phosphatidyqinositol‐3 kinase/protein kinase B (PI3K/Akt) signaling pathway. Cell Viability Assaysup>Cell Line:H9c2 cells Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L Incubation Time:24 h Result:Attenuated Ang II‐induced toxicity in H9c2 cells Apoptosis Analysis Cell Line:H9c2 cells Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L Incubation Time:24 h Result:Decreased apoptotic cells, and prevented Ang II‐induced cytotoxicity that involves modulation of the PI3K/Akt pathway.Western Blot Analysis Cell Line:H9c2 cells Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L Incubation Time:24 h Result:Expressed the protein and mRNAs of CCK and both its receptors in H9c2 cells.RT-PCR Cell Line:H9c2 cells Concentration:0.001, 0.01, 0.1, 1, 10, or 100 μmol/L Incubation Time:24 h Result:Increased the protein and mRNA expression levels of CCK and decreased CCK 1 receptor expression levels at both the protein and mRNA levels with Ang II stimulation markedly.

Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) alleviates fibrosis in the noninfarcted regions and delay the left ventricular remodeling and the progress of heart failure in a MI rat model. Animal Model:MI rat modelDosage:50 μg/kg Administration:i.p.; 50 μg/kg/d; for 4 weeks Result:Had significant inhibitory effect on myocardial fibrosis in noninfarcted areas.

Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium

Others

Other Targets

——

——

——

70706-98-8

1160.3

C49H65N11O16S3

>98% (HPLC)

H2O : 12.5 mg/mL (10.77 mM; Need ultrasonic)

——

Sequence:Asp-{SO3H-Tyr}-Met-Gly-Trp-Met-Asp-Phe-NH2

(-20℃)

With Ice Pack

≥ 2 years